Peking Union Medical College Hospital: Lung Neoplasms trials

The registry lists 27 Lung Neoplasms studies with Peking Union Medical College Hospital as lead sponsor. 14 are open to participants now and 0 have results posted.

Early Phase 1 6Phase 1 1Phase 2 8Phase 3 1Phase 4 1No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ⁶⁸Ga-DPA in the Lung Cancer DiagnosisEnrolling by invitationNCT07023068Early Phase 1
• Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06931145Phase 4
• Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingNCT06752408Phase 2
• Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsRecruitingNCT06674343Phase 3
• Comparing Valve-regulated Pleural Drainage to Traditional Closed Chest Tube DrainageRecruitingNCT06410716Not applicable
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICIRecruitingNCT06388031Phase 2
• Serplulimab Combined With CCRT for LS-SCLC.RecruitingNCT06295926Phase 2
• Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung CancerRecruitingNCT06194630Early Phase 1
• COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker ResearchRecruitingNCT06168032Not applicable
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
• 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer PatientsRecruitingNCT05543954Early Phase 1
• Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung CancerRecruitingNCT05445310Phase 2
• Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
• Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)RecruitingNCT03334864
• Effects of Protein on Muscle, Gut Microbiota and Clinical Outcome in Patients With Lung Cancer-related SarcopeniaStatus unknownNCT05771207Not applicable
• irAE Prediction of Anti-PD-1/L1 in Lung CancerStatus unknownNCT05288569
• A Real-world Study of Durvalumab for Lung Cancer in ChinaStatus unknownNCT04672759
• Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLCStatus unknownNCT04663438
• Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics ModelsStatus unknownNCT04646837Phase 1/2
• Comparing the Impact of Multimodal Prehabilitation to Aerobic Training on Patients Undergoing Thoracoscopic LobectomyStatus unknownNCT04049942Not applicable
• The Impact of Trimodal Prehabilitation Strategy on Patients Undergoing Thoracoscopic LobectomyCompletedNCT03068507Not applicable
• Dual SSTR2 and Integrin αvβ3 Targeting PET/CT ImagingStatus unknownNCT02817945Early Phase 1
• A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal MetastasisStatus unknownNCT02803619
• Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung CancerStatus unknownNCT01752517
• Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer PatientsStatus unknownNCT01749072Phase 2
• 99mTc-3PRGD2 SPECT/CT in Lung Cancer PatientsStatus unknownNCT01737112Early Phase 1
• 68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer PatientsStatus unknownNCT01527058Early Phase 1